Shannuo Li Presents Immunotherapy Research at the ASH Annual Meeting
Molecular Pharmaceutics Ph.D. student Shannuo Li presented her research at the American Society of Hematology (ASH) Annual Meeting in December 2025. She delivered her oral presentation on December 8, focused on improving immune cell–based therapies for multiple myeloma.
Shannuo’s research centers on the development of Self-Assembled Immune Cell Engagers (SITE), a modular immunotherapy platform designed to enhance both the safety and effectiveness of immune-engaging cancer treatments. SITE can engage T cells, natural killer (NK) cells, and macrophages, and uniquely separates tumor targeting and immune activation into sequentially administered components. This strategy enables localized immune activation at tumor sites while reducing off-target effects and lowering the risk of cytokine release syndrome.
This work was conducted under the mentorship of Dr. Jindřich Kopeček and Dr. Jiyuan Yang, with contributions from collaborators across the University of Utah and Huntsman Cancer Institute. Shannuo shared that presenting this research at ASH was especially meaningful, as the SITE platform addresses a critical clinical challenge in immunotherapy and demonstrates strong translational potential.
Congratulations to Shannuo on this outstanding presentation and for representing the Department of Molecular Pharmaceutics at a major international conference!
